Literature DB >> 9649223

Identification and characterization of autoantibodies against catalase and alpha-enolase in patients with primary sclerosing cholangitis.

T Orth1, R Kellner, O Diekmann, J Faust, K H Meyer zum Büschenfelde, W J Mayet.   

Abstract

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown aetiology. Recent studies have shown that genetic factors and both cellular and humoral immunological abnormalities are important in the pathogenesis of PSC. The most prominent autoantibodies in PSC are anti-neutrophil cytoplasmic antibodies (ANCA). The autoepitopes of ANCA in PSC are not well defined. The aim of this study was to identify corresponding ANCA autoantigens in patients with PSC. A biochemical approach with enrichment and partial purification of soluble neutrophil proteins, detection of autoantibodies by Western blot and partial amino acid sequencing were used. Two new autoantigen/autoantibody systems in patients with PSC were detected: catalase and alpha-enolase. The presence of catalase autoantibodies in 9/15 (60%) and alpha-enolase autoantibodies in 4/15 (27%) was confirmed by ELISA and Western blot. Furthermore, we showed immunoreactions of PSC sera with human biliary epithelial cells, showed the reduction of fluorescence in anti-catalase absorption experiments and observed partial co-localization of anti-catalase antibodies and PSC sera in double-staining experiments on biliary epithelial cells. The anti-catalase antibody-positive PSC patients had a more severe course of disease with a significantly higher alkaline phosphatase compared with the anti-catalase-negative PSC patients (P < 0.06). All ulcerative colitis control sera were anti-catalase antibody-negative. The identified antigens catalase and alpha-enolase can partly explain the ANCA fluorescence on ethanol-fixed and formaldehyde-fixed granulocytes in patients with PSC. Catalase is an important anti-oxidant enzyme and prevents cell damage from highly reactive oxygen-derived free radicals. Catalase autoantibodies might play a pathogenic role in patients with PSC. Our findings support the hypothesis that oxidative stress is one of the pathogenic mechanisms in patients with PSC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9649223      PMCID: PMC1904984          DOI: 10.1046/j.1365-2249.1998.00583.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  Investigation of the specific autoantigen of primary sclerosing cholangitis by western blot and immunoprecipitation.

Authors:  S K Lo; R W Chapman; K A Fleming
Journal:  Hepatology       Date:  1993-08       Impact factor: 17.425

2.  Human neutrophil collagenase.

Authors:  H Tschesche
Journal:  Methods Enzymol       Date:  1995       Impact factor: 1.600

3.  Neutrophil cytoplasmic antibodies (p-ANCA) in ulcerative colitis.

Authors:  P M Ellerbroek; M Oudkerk Pool; B U Ridwan; K M Dolman; B M von Blomberg; A E von dem Borne; S G Meuwissen; R Goldschmeding
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

Review 4.  Current concepts in primary sclerosing cholangitis.

Authors:  R H Wiesner
Journal:  Mayo Clin Proc       Date:  1994-10       Impact factor: 7.616

5.  Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates.

Authors:  A H Mulder; J Broekroelofs; G Horst; P C Limburg; G F Nelis; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

6.  Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells.

Authors:  W J Mayet; K H Meyer zum Büschenfelde
Journal:  Clin Exp Immunol       Date:  1993-12       Impact factor: 4.330

7.  Changes in the localization of catalase during differentiation of neutrophilic granulocytes.

Authors:  C A Ballinger; C Mendis-Handagama; J R Kalmar; R R Arnold; J M Kinkade
Journal:  Blood       Date:  1994-05-01       Impact factor: 22.113

8.  Human endothelial cells express proteinase 3, the target antigen of anticytoplasmic antibodies in Wegener's granulomatosis.

Authors:  W J Mayet; E Csernok; C Szymkowiak; W L Gross; K H Meyer zum Büschenfelde
Journal:  Blood       Date:  1993-08-15       Impact factor: 22.113

Review 9.  Etiology and pathogenesis in primary sclerosing cholangitis.

Authors:  K M Boberg; K E Lundin; E Schrumpf
Journal:  Scand J Gastroenterol Suppl       Date:  1994

Review 10.  Importance of Se-glutathione peroxidase, catalase, and Cu/Zn-SOD for cell survival against oxidative stress.

Authors:  C Michiels; M Raes; O Toussaint; J Remacle
Journal:  Free Radic Biol Med       Date:  1994-09       Impact factor: 7.376

View more
  18 in total

Review 1.  Primary sclerosing cholangitis.

Authors:  S A Mitchell; R W Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 2.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

3.  IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis.

Authors:  C Schwarze; B Terjung; P Lilienweiss; U Beuers; V Herzog; T Sauerbruch; U Spengler
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

4.  Circulating antibodies against alpha-enolase in patients with primary membranous nephropathy (MN).

Authors:  H Wakui; H Imai; A Komatsuda; A B Miura
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

5.  The role of anti-alpha-enolase autoantibodies in pathogenicity of autoimmune-mediated retinopathy.

Authors:  Agnieszka Magrys; Thimmappa Anekonda; Gaoying Ren; Grazyna Adamus
Journal:  J Clin Immunol       Date:  2007-01-19       Impact factor: 8.317

Review 6.  Autoantibodies in primary sclerosing cholangitis.

Authors:  Johannes-Roksund Hov; Kirsten-Muri Boberg; Tom-H Karlsen
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

7.  Chemical unfolding of enolase from Saccharomyces cerevisiae exhibits a three-state model.

Authors:  Dénison S Sánchez-Miguel; Jahir Romero-Jiménez; César A Reyes-López; Ana Lilia Cabrera-Avila; Normande Carrillo-Ibarra; Claudia G Benítez-Cardoza
Journal:  Protein J       Date:  2010-01       Impact factor: 2.371

Review 8.  Pathophysiological basis for antioxidant therapy in chronic liver disease.

Authors:  Jesús Medina; Ricardo Moreno-Otero
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  Using immunoproteomics to identify alpha-enolase as an autoantigen in liver fibrosis.

Authors:  Bo Peng; Xueyong Huang; Ernesto S Nakayasu; John R Petersen; Suimin Qiu; Igor C Almeida; Jian-Ying Zhang
Journal:  J Proteome Res       Date:  2013-03-15       Impact factor: 4.466

Review 10.  The immunobiology of primary sclerosing cholangitis.

Authors:  Jonathan H Aron; Christopher L Bowlus
Journal:  Semin Immunopathol       Date:  2009-05-26       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.